REVISIONS TO PROFILE AND REFLEX COMPONENTS
Encephalopathy, Autoimmune Evaluation, CSF
Order Code: ENC2
Fee Code: AA270 (CPT 86341), AA271 (CPT 86255) x19
Reference Laboratory: Mayo ENC2
Effective January 31, 2023, there will be additions and deletions to the profile and potential reflex tests for the Encephalopathy, Autoimmune Evaluation, CSF referred to Mayo Clinic Laboratories as follows:
Testing to be added to Profile Information:
• NCDIC: Neurochondrin Antibody, Tissue Immunofluorescence, Spinal Fluid (CPT 86255)
• SP7IC: Septin-7 Antibody, Tissue Immunofluorescence, Spinal Fluid (CPT 86255)
Testing to be added to Reflex Tests:
• AGNTC: Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Spinal Fluid
• AN1TC: Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Spinal Fluid
• AN2TC: Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Spinal Fluid
• AN3TC: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Spinal Fluid
• APHTC: Amphiphysin Antibody Titer Assay, Spinal Fluid
• CRMTC: Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Spinal Fluid
• NCDCC: Neurochondrin Antibody, Cell-Binding Assay, Spinal Fluid
• NCDTC: Neurochondrin Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
• PC1TC: Purkinje Cell Cytoplasmic Antibody Type 1 (PCA-1) Titer, Spinal Fluid
• PC2TC: Purkinje Cell Cytoplasmic Antibody Type 2 (PCA-2) Titer, Spinal Fluid
• PCTTC: Purkinje Cell Cytoplasmic Antibody, Type Tr (PCA-Tr) Titer, Spinal Fluid
• SP7CC: Septin-7 Antibody, Cell-Binding Assay, Spinal Fluid
• SP7TC: Septin-7 Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
Also note new ordering guidelines: This testing is intended to be ordered in adult patients. If this test is ordered on a patient younger than 18 years of age, this test will be cancelled and automatically reordered by the laboratory as Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, CSF (test ID PCDEC). Mayo Clinic Laboratories pediatric autoimmune CNS disorders evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.